Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab effectiveness after suboptimal response to satralizumab in AQP4+ NMOSD
jRCTs031230647Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Relapse-free proportion at 12 months. Started Mar 2024; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCTs031230647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230647.